Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=75025870&loc=d3e40691-111596

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=75027002&loc=d3e40346-111594

Name:	us-gaap_CostMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Cost Method Investment - Additional Information (Detail) - USD ($)	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Cost Method Investments [Line Items]
Cost method investment	$ 8,500,000		$ 0
Viracta Therapeutics, Inc. \| Series B Convertible Preferred Stock
Schedule Of Cost Method Investments [Line Items]
Cost method investment		$ 8,500,000
Viracta Therapeutics, Inc. \| Series B Convertible Preferred Stock \| Maximum
Schedule Of Cost Method Investments [Line Items]
Option to purchase additional shares under cost method investment	$ 8,500,000